Abstract
Braun is a global manufacturer of healthcare products for hospitals and the
non-clinical sector. This report provides a full review of the company' s
activities.
B. Braun Melsungen AG (Braun), headquartered in Melsungen, Germany, is a
global manufacturer of healthcare products for hospitals and the non-clinical
sector, with approximately 30,000 employees worldwide. The company' s portfolio
comprises more than 30,000 products, including anaesthetics, infusion systems,
infusion solutions, surgical instruments, orthopaedic implants, equipment for
extracorporeal treatment, sutures, products for wound care and disinfection,
as well as services such as consultancy for hospitals and patients, dialysis
centres or professional training and education. Braun also has an OEM business
through which it provides a wide range of products and contract manufacturing
services. In fiscal 2004, ended 31st December 2004, Braun' s sales rose by 5.5%
to EUR 2.8 billion, driven by strong sales in Europe, excluding Germany, while
operating profit rose by 23.1% to EUR 213.1 million.
Braun' s products and services are organised within four principal divisions:
the Hospital Care division, Aesculap, the Out Patient Market (OPM) division
and the MedTech division.
Braun' s largest division, the Hospital Care division, offers infusion
solutions, anaesthetics, infusion apparatus and accessories. In fiscal 2004,
sales at the Hospital Care division rose by 3.9% to EUR 1.3 billion and
accounted for 48.2% of the company' s total revenue.
The Aesculap division offers surgical instruments, suture materials, spinal
implants and navigation systems. In fiscal 2004, Aesculap' s sales rose by 4%
to EUR 811.8 million and accounted for 29.1% of Braun' s total revenue.
Sales in the OPM division, which offers products for enteral and parenteral
nutrition, wound care and diabetes, rose by 4.9% to EUR 374.3 million in
fiscal 2004 and accounted for 13.4% of Braun' s total revenue.
The MedTech division offers product systems and services for extracorporeal
blood treatment. Sales at MedTech increased by 24% to EUR 248.7 million in
2004 and accounted for 8.9% of Braun' s total revenue.
This report provides a complete review of the company' s activities, from its
origins to its latest corporate activity, including mergers and acquisitions,
agreements, divestitures, major purchasing contracts and litigation. Sections
are included on products, international activities and R&D, as well as a full,
in-depth five year financial analysis.
View Cart
